Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2021

View Archived Issues

UCART-19 shows antileukemic activity in heavily pretreated pediatric and adult patients

JMX-0207 inhibits Zika virus both in vitro and in vivo

Inhaled phage therapy YPT-01 enters phase I/II trial to treat P. aeruginosa in cystic fibrosis

FDA clears IND for phase I study of DA-01 in advanced Parkinson's disease

CARs with switches

FDA issues clinical hold letter related to an IND for NL-201

Positive phase IIb data presented for DBI-001 in tinea pedis

Dana-Farber Cancer Institute patents EGFR allosteric inhibitors

Bristol Myers Squibb discloses new FPR2 agonists

Calithera Biosciences presents CD73 inhibitors

Indian researchers patent new lipoxygenase inhibitors

Antibodies target fibrotic and autoimmune diseases

CAR-MICA/B immunotherapy controls hematopoietic and solid tumor progression in vivo

AMMS synthesizes new adenosine A2A receptor agonists

Discovery of non-sugar-derived OGA inhibitors for neurodegenerative disorders

U.K. approval of COVID-19 Vaccine Moderna

Tocilizumab to be used in U.K. for ICU patients with COVID-19

Open-label study data show patients treated with LB-1148 had shorter hospital stay

Preclinical data presented for CD30-targeting CAR T cells as lymphoma immunotherapy

Ultragenyx updates gene therapy program progress

E.U. approval for Xofluza for treatment and postexposure prophylaxis of influenza

Celon reports topline phase II data on Falkieri in bipolar depression

Ideaya submits IND for phase I evaluation of MAT2A inhibitor IDE-397

Phase II TRAILBLAZER-ALZ trial of donanemab in Alzheimer's meets primary endpoint

Cara opens phase II trial of oral difelikefalin for notalgia paresthetica pruritus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
Research grants support early clinical trials of ALS treatments
BioWorld Science
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...